Alexion adds to pipeline with $1.2bn Syntimmune buy

Alexion is in the midst of a concerted effort to build its pipeline as it prepares for the possible loss of patent protection for Soliris (eculizumab), its biggest-selling product. ... Used to treat paroxysmal nocturnal haemoglobinuria (PNH) and

The year of the blockbuster

These include Juno Therapeutics’ CAR T-cell therapy, lisocabtagene maraleucel, for diffuse large B-cell lymphoma, and Alexion’s next-generation Soliris treatment, ravulizumab, for paroxysmal nocturnal haemoglobinuria.

Alexion uses priority review voucher for Soliris follow-up

Files ravulizumab for paroxysmal nocturnal haemoglobinuria. Alexion is pulling out all the stops to get speedy approval for a follow-up to its rare blood disorder therapy Soliris, using a coveted ... The company has filed ravulizumab ( ALXN1210) for

Morning brief: Sanofi's shaky start, pharma begins talks with UK government and more

gMG). It also unveiled positive top-line data from its Phase III trial of ALXN1210, a long-acting form of its flagship treatment Soliris. ... ALXN1210 in patients with paroxysmal nocturnal hemoglobinuria (PNH) need only be administered once every eight

1 2 3 4 5 6 [ Next 5 results ]